Formosa Laboratories Executive and Leadership Team

Chih-Ping Yang, the Chief Executive Officer at Formosa Laboratories, directs the overarching corporate strategy and global market positioning. This leadership role involves guiding the company's expansion into new therapeutic areas and solidifying its status as a premier API and UV-filter manufacturer. Yang oversees the integration of advanced manufacturing technologies within the modern facilities near Taipei, ensuring adherence to rigorous GMP compliance standards approved by international bodies including the US FDA and PMDA of Japan. The Chief Executive Officer's focus extends to fostering innovation in custom synthesis services, from initial process development through to full commercial production, providing comprehensive documentation support for clients. By driving strategic initiatives, Chih-Ping Yang ensures Formosa Laboratories maintains its competitive edge and commitment to delivering high-quality pharmaceutical ingredients and specialty chemicals to a global clientele.

Chen-Yu Cheng, the President at Formosa Laboratories, spearheads the operational execution and efficiency across all manufacturing divisions. This executive guides the production of a diverse portfolio of APIs, including Vitamin D derivatives, Balsalazide, and Montelukast, alongside key UV-filter products like avobenzone and Octinoxate. Cheng ensures that all operations maintain the highest levels of GMP compliance, a critical factor for approvals from Taiwan's DOH, Germany's BGV, and Japan's PMDA. The President's responsibilities encompass optimizing supply chain logistics and enhancing production capabilities within the company's state-of-the-art facilities. By focusing on operational excellence, Chen-Yu Cheng directly supports the company's capacity to provide custom synthesis services, managing projects from early-stage development to large-scale commercial output. This leadership ensures Formosa Laboratories consistently meets global demand for its specialized chemical products.

C.P. Yang, the President at Formosa Laboratories, drives the strategic development and commercialization of the company's extensive product lines. This leadership position involves identifying new market opportunities for both APIs and UV-filters, expanding the global reach of products such as Colesevelam and Sevelamer. Yang oversees the rigorous quality assurance protocols that underpin the company's GMP compliance, essential for approvals from regulatory bodies like the US FDA and EDQM. The President's mandate includes fostering strong relationships with international partners and clients, ensuring seamless delivery of custom synthesis projects from process development to commercial scale. By championing innovation and market penetration, C.P. Yang ensures Formosa Laboratories remains a leading global supplier of critical pharmaceutical ingredients and specialty chemicals, contributing significantly to advancements in healthcare and personal care industries.

C.Y. Cheng, the President at Formosa Laboratories, focuses on enhancing the company's research and development initiatives and expanding its custom synthesis capabilities. This executive directs efforts to innovate within the production of complex APIs, including Vitamin D derivatives and Mycophenolate Mofetil, and advanced UV-filters. Cheng ensures that the company's modern facilities near Taipei operate at peak efficiency, maintaining strict GMP compliance validated by global health authorities. The President's role involves overseeing the technical aspects of custom synthesis projects, guiding teams from process optimization to full-scale commercial manufacturing with comprehensive documentation support. By driving scientific advancement and operational refinement, C.Y. Cheng strengthens Formosa Laboratories' position as a trusted partner for specialty chemical production and a key contributor to the pharmaceutical sector worldwide.